Literature DB >> 15829965

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

Vassilis G Gorgoulis1, Leandros-Vassilios F Vassiliou, Panagiotis Karakaidos, Panayotis Zacharatos, Athanassios Kotsinas, Triantafillos Liloglou, Monica Venere, Richard A Ditullio, Nikolaos G Kastrinakis, Brynn Levy, Dimitris Kletsas, Akihiro Yoneta, Meenhard Herlyn, Christos Kittas, Thanos D Halazonetis.   

Abstract

DNA damage checkpoint genes, such as p53, are frequently mutated in human cancer, but the selective pressure for their inactivation remains elusive. We analysed a panel of human lung hyperplasias, all of which retained wild-type p53 genes and had no signs of gross chromosomal instability, and found signs of a DNA damage response, including histone H2AX and Chk2 phosphorylation, p53 accumulation, focal staining of p53 binding protein 1 (53BP1) and apoptosis. Progression to carcinoma was associated with p53 or 53BP1 inactivation and decreased apoptosis. A DNA damage response was also observed in dysplastic nevi and in human skin xenografts, in which hyperplasia was induced by overexpression of growth factors. Both lung and experimentally-induced skin hyperplasias showed allelic imbalance at loci that are prone to DNA double-strand break formation when DNA replication is compromised (common fragile sites). We propose that, from its earliest stages, cancer development is associated with DNA replication stress, which leads to DNA double-strand breaks, genomic instability and selective pressure for p53 mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829965     DOI: 10.1038/nature03485

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  904 in total

Review 1.  Using mice to examine p53 functions in cancer, aging, and longevity.

Authors:  Lawrence A Donehower
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11-04       Impact factor: 10.005

2.  The oncogenic phosphatase WIP1 negatively regulates nucleotide excision repair.

Authors:  Thuy-Ai Nguyen; Scott D Slattery; Sung-Hwan Moon; Yolanda F Darlington; Xiongbin Lu; Lawrence A Donehower
Journal:  DNA Repair (Amst)       Date:  2010-05-06

3.  Clld7, a candidate tumor suppressor on chromosome 13q14, regulates pathways of DNA damage/repair and apoptosis.

Authors:  Xiaobo Zhou; Karl Münger
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 4.  Effect of NKG2D ligand expression on host immune responses.

Authors:  Marine Champsaur; Lewis L Lanier
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

5.  TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection.

Authors:  Apostolos Klinakis; Theodoros Rampias
Journal:  EBioMedicine       Date:  2020-07-30       Impact factor: 8.143

6.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

7.  Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.

Authors:  George T Lountos; Joseph E Tropea; Di Zhang; Andrew G Jobson; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

Review 8.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

9.  p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression.

Authors:  Phillippe P Gonzalez; Jungeun Kim; Rui Pedro Galvao; Nichola Cruickshanks; Roger Abounader; Hui Zong
Journal:  Glia       Date:  2018-02-02       Impact factor: 7.452

10.  ZWINT is the next potential target for lung cancer therapy.

Authors:  Fang Peng; Qiang Li; Shao-Qing Niu; Guo-Ping Shen; Ying Luo; Ming Chen; Yong Bao
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-14       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.